![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Assaf-Harofeh Medical Center |
---|---|
Information provided by: | Assaf-Harofeh Medical Center |
ClinicalTrials.gov Identifier: | NCT00443105 |
The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.
Condition | Intervention | Phase |
---|---|---|
Allergic Conjunctivitis |
Drug: Tacrolimus 0.03% ointment (Protopic) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Ages Eligible for Study: | 5 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Assaf Harofeh Medical Center, Department of Ophthalmology | |
Zerifin, Israel, 70300 |
Principal Investigator: | David Zadok, MD | Assaf Harofeh Medical Center, Tel Aviv University |
Study ID Numbers: | 20050321 |
Study First Received: | March 2, 2007 |
Last Updated: | March 2, 2007 |
ClinicalTrials.gov Identifier: | NCT00443105 |
Health Authority: | Israel: Ministry of Health |
Hypersensitivity Conjunctivitis, Allergic Eye Diseases Hypersensitivity, Immediate |
Tacrolimus Conjunctivitis Conjunctival Diseases |
Immunologic Factors Immune System Diseases Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |